{
  "docId": "019de070-0ed4-7638-a889-7a7fc1ddc308",
  "docSlug": "5ce7ec09cf381a935cffcd873943f8c1",
  "documentTitle": "Aeglea BioTherapeutics | Results Presentation Deck | 13 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 11,
  "pageCount": 13,
  "prevPage": 10,
  "nextPage": 12,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 48,
  "notes": "The table uses color-coding to indicate responder status based on MCID thresholds.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-0ed4-7638-a889-7a7fc1ddc308/11",
  "deckHref": "/decks/019de070-0ed4-7638-a889-7a7fc1ddc308",
  "deckJsonHref": "/decks/019de070-0ed4-7638-a889-7a7fc1ddc308.json",
  "deckAnchorHref": "/decks/019de070-0ed4-7638-a889-7a7fc1ddc308#slide-11",
  "components": [
    {
      "bbox": {
        "h": 0.23,
        "w": 0.342,
        "x": 0.02,
        "y": 0.275
      },
      "kind": "callout",
      "text": "Overall clinical response rate: 20 Week Analysis: 11/14 (79%) 56 Week Analysis: 11/13 (85%)",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7b570ddf-ef4b-40ca-a4b2-04f820ccaf6e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.8,
        "x": 0.2,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "Responder (≥1 MCID Increase) | ≥1 MCID decrease | Not assessed | <1 MCID increase | data not available *MCID for 6MWT = 9%; MCID for GMFM Part D is 2.4, 3.3, and 1.5 for GMFCS Levels I, II and III, respectively; MCID for GMFM Part E is 4.0, 2.8, and 1.8 for GMFCS Levels I, II and III, respectively. Maximum values for GMFM-D and GMFM-E are 39 and 72, respectively.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5e2fd575-49da-4d96-b365-071769f19f8d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.36,
        "y": 0.2
      },
      "kind": "table",
      "text": "Patient-level data for 6MWT, GMFM-D, GMFM-E, and GMFCS",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bf4dbc2-d0b5-403e-9b8b-d79e1ac85c07",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "Pegzilarginase Demonstrates Durable Clinical Response at 56 Week Analysis",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc77551a-6098-423b-b83a-5acec265488b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 11,
      "from": 5,
      "beatId": "ab1a9bb2-2594-47ca-80cf-39fc8cef5a32",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Solution",
      "beatSlug": "problem-agitate-solution-solution-provide-relief",
      "evidence": "The presentation showcases Pegzilarginase as a solution",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}